TY - JOUR
T1 - The impact of SARS-CoV-2 on the cystic fibrosis foundation therapeutics development network
AU - Pearson, Kelsie
AU - Mayer-Hamblett, Nicole
AU - Goss, Christopher H.
AU - Retsch-Bogart, George Z.
AU - VanDalfsen, Jill M.
AU - Burks, Patricia
AU - Rosenbluth, Daniel
AU - Clancy, John Paul
AU - Hoffman, Amy
AU - Nichols, David P.
N1 - Funding Information:
This work was supported by the Cystic Fibrosis Foundation (CFF). NMH, CHG, and DPN were also supported by National Institutes of Health (NIH) grants P30 DK 089507. CHG is also supported by the following federal awards: UM1HL119073, UL1TR000423, R01FD003704 and R01FD006848.
Funding Information:
NMH has received grant funding from the Cystic Fibrosis Foundation (CFF) and National Institutes of Health (NIH). CHG reports grant funding from CFF, European Commission, National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Research Resources, Gilead Sciences, Novartis, NIH, Food and Drug Administration, Boehringer Ingelheim, Vertex Pharmaceuticals. None of the work presented in this short communication was influenced by the funding sources reported by CHG. KP, GZRB, JMVD, PB, DR., JPC, AH, and DPN have nothing to disclose related to this work.
Publisher Copyright:
© 2020 The Authors
PY - 2021/3
Y1 - 2021/3
N2 - The Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) global pandemic significantly impacted CF clinical research within the Cystic Fibrosis Foundation Therapeutics Development Network (CFF TDN). A Research Electronic Data Capture (REDCap) survey was developed and sent to network sites to monitor and understand the impact on research teams, ongoing and anticipated clinical research, and specific clinical and research procedures. Key findings indicated an early impact on participant enrollment, research team stability, and procedures such as spirometry and sputum induction. These trends steadily improved over the months as research activities began to recover across the TDN. While SARS-CoV-2 created a significant challenge it also highlights new opportunities to expand CF research with greater focus on data collection outside of research centers and increased access for remote participation.
AB - The Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) global pandemic significantly impacted CF clinical research within the Cystic Fibrosis Foundation Therapeutics Development Network (CFF TDN). A Research Electronic Data Capture (REDCap) survey was developed and sent to network sites to monitor and understand the impact on research teams, ongoing and anticipated clinical research, and specific clinical and research procedures. Key findings indicated an early impact on participant enrollment, research team stability, and procedures such as spirometry and sputum induction. These trends steadily improved over the months as research activities began to recover across the TDN. While SARS-CoV-2 created a significant challenge it also highlights new opportunities to expand CF research with greater focus on data collection outside of research centers and increased access for remote participation.
KW - Clinical research
KW - Coronavirus
KW - Cystic fibrosis
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85098197617&partnerID=8YFLogxK
U2 - 10.1016/j.jcf.2020.12.007
DO - 10.1016/j.jcf.2020.12.007
M3 - Article
C2 - 33349583
AN - SCOPUS:85098197617
SN - 1569-1993
VL - 20
SP - 195
EP - 197
JO - Journal of Cystic Fibrosis
JF - Journal of Cystic Fibrosis
IS - 2
ER -